

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 15**

---

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION  
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934  
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number 001-39746

---

**SIGILON THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

---

100 Binney Street, Suite 600

Cambridge, MA 02142

Telephone: (617) 336-7540

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

---

Common stock, \$0.001 par value per share

(Title of each class of securities covered by this Form)

---

None

(Title of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

---

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)	<input checked="" type="checkbox"/>
Rule 12g-4(a)(2)	<input type="checkbox"/>
Rule 12h-3(b)(1)(i)	<input checked="" type="checkbox"/>
Rule 12h-3(b)(1)(ii)	<input type="checkbox"/>
Rule 15d-6	<input type="checkbox"/>
Rule 15d-22(b)	<input type="checkbox"/>

Approximate number of holders of record as of the certification or notice date: One holder

Pursuant to the requirements of the Securities Exchange Act of 1934, Sigilon Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: August 21, 2023

**Sigilon Therapeutics, Inc.**

By: /s/ Philip L. Johnson

Name: Philip L. Johnson

Title: President

---

---